Granulomatous Disease, Chronic
Recent clinical, regulatory, research and industry developments relating to this disease.
Unlocking the power of NOX2: A comprehensive review on its role in immune regulation.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes2
- Granulomatous Disease, Chronic1
- NADPH Oxidases1
Leading journals1
- Redox biology1
Leading researchers4
- Bode K1
- Hauri-Hohl M1
- Jaquet V1
- Weyd H1
Affiliations (unnormalised)4
- Centre Médical Universitaire1
- Clinical Cooperation Unit Applied Tumor Immunity D1201
- Joslin Diabetes Center1
- University Children's Hospital Zurich - Eleonore Foundation & Children`s Research Center (CRC)1
Reference
Authoritative identity, definition & identifiers.
A defect of leukocyte function in which phagocytic cells ingest but fail to digest bacteria, resulting in recurring bacterial infections with granuloma formation. When chronic granulomatous disease is caused by mutations in the CYBB gene, the condition is inherited in an X-linked recessive pattern. When chronic granulomatous disease is caused by CYBA, NCF1, NCF2, or NCF4 gene mutations, the condition is inherited in an autosomal recessive pattern.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.